AstraZeneca PLC - Depreciation and Amortization Expense

AstraZeneca PLC's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Depreciation-and-Amortization-Expense" stands at 6.56 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

AstraZeneca PLC's third quarter result of 1.55 Billion USD for the item "Depreciation and Amortization Expense" represents an increase of 11.52 percent compared to it's second quarter result.

Also, AstraZeneca PLC's third quarter result of 1.55 Billion USD for the item "Depreciation and Amortization Expense" represents a decrease of -14.75 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), AstraZeneca PLC's third quarter result of 6.56 Billion USD for the item "Depreciation and Amortization Expense" represents a decrease of -3.93 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 25.53 percent compared to the value the year prior.
The 1 year change in percent is 25.53.
The 3 year change in percent is 5.93.
The 5 year change in percent is 64.18.
The 10 year change in percent is 107.76.

The Serie's long term average value is 4.05 Billion United States Dollars. It's latest available value, on 09/30/2025, is 61.86 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2016, to it's latest available value, on 09/30/2025, is +178.28%.
The Serie's change in percent from it's maximum value, on 06/30/2022, to it's latest available value, on 09/30/2025, is -14.22%.